HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | PTD-DBM |
|---|---|
| CAS number | 1609454-11-6 |
| Molecular formula | C124H225N61O28S2 |
| Molecular weight | 3082.62 g/mol |
| Sequence | RRRRRRRRGGGGRKTGHQICKFRKC |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 1mg |
| Documentation | Batch-document availability confirmed by product, specification and applicable lot |
| Distribution scope | Research use, worldwide |
| Storage | Supplied as a lyophilized powder; stable for short ambient-temperature transit. Store long-term at -20°C, protected from light and moisture. After reconstitution, keep at 2–8°C for short-term use or aliquot and store at -20°C to avoid repeated freeze–thaw cycles. The two cysteine residues make the peptide oxidation-sensitive — minimize air exposure of solutions. |
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
PTD-DBM is a cell-penetrating peptide built from an octa-arginine protein transduction domain (PTD), a tetraglycine linker, and a Dishevelled-binding motif (DBM). In research models it competes with the endogenous protein CXXC5 for the Dvl PDZ domain, relieving CXXC5's negative-feedback inhibition of the Wnt/β-catenin pathway and increasing β-catenin activity.
Documentation
batch-document availability confirmed by product, specification and applicable lot. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the PTD-DBM reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Each batch ships as a lyophilized powder with a Certificate of Analysis reporting HPLC purity (typically ≥99%) and identity confirmed by mass spectrometry. COA, and where required TDS/SDS, water-content and residual-solvent data, are provided on request to support RFQ and regulatory files.
PTD-DBM is stocked in 1mg vials with a minimum order quantity of 50 kits (500 vials). Larger research quantities and bulk or gram-scale custom synthesis are quoted on RFQ.
Yes. We offer custom fill weights, unbranded or client-branded vials and labeling, and lyophilization to spec for private-label and contract-manufacturing programs. Documentation packages can be tailored to destination-market requirements.
PTD-DBM is a 25-residue synthetic peptide (CAS 1609454-11-6), molecular formula C124H225N61O28S2, average mass ≈ 3082.6 g/mol, sequence RRRRRRRRGGGGRKTGHQICKFRKC (octa-arginine PTD + GGGG linker + Dishevelled-binding motif). It is typically supplied as the acetate or TFA salt; salt form and counter-ion can be specified on request.
No. PTD-DBM is offered strictly as a research-use-only / for-laboratory-research material. It is not a drug, cosmetic, or dietary product and is not approved by the FDA or other regulators for consumer or veterinary use. Buyers are responsible for lawful handling and compliance in their jurisdiction.
Related compounds
COA library search
The public COA library is being expanded by product and specification. Use the search link below to check current public records for this item.